Anal Squamous Cell Carcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ANL017 MIFTS: 49	Anal Squamous Cell Carcinoma Categories: Cancer diseases, Gastrointestinal diseases, Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Anal Squamous Cell Carcinoma

MalaCards integrated aliases for Anal Squamous Cell Carcinoma:

Name: Anal Squamous Cell Carcinoma ¹² ¹⁵ ¹⁷ ⁷⁴

Epidermoid Anal Carcinoma ¹²

Carcinoma of Anal Margin ⁷⁴

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases Skin diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:5525

NCIt ⁵¹ C9161

EFO ¹⁷ EFO_1000081

UMLS ⁷⁴ C0349534 C1412036

Sources

Summaries for Anal Squamous Cell Carcinoma

Disease Ontology : ¹² An anal carcinoma that arises near the squamocolumnar junction.

MalaCards based summary : Anal Squamous Cell Carcinoma, also known as epidermoid anal carcinoma, is related to squamous cell carcinoma and suppressor of tumorigenicity 3. An important gene associated with Anal Squamous Cell Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Human cytomegalovirus infection. The drugs Immunologic Factors and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include lymph node, testes and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Sources

Related Diseases for Anal Squamous Cell Carcinoma

Diseases related to Anal Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 170)

#	Related Disease	Score	Top Affiliating Genes
1	squamous cell carcinoma	31.0	AKT1 CDKN2A PIK3CA TP53
2	suppressor of tumorigenicity 3	30.4	CDKN2A TP53
3	in situ carcinoma	30.3	CDKN2A TP53
4	cervix carcinoma	30.2	CDKN2A TP53
5	adenocarcinoma	28.8	AKT1 APC CDKN2A MLH1 PIK3CA TP53
6	bladder squamous cell carcinoma	10.3	CDKN2A TP53
7	keratinizing squamous cell carcinoma	10.3	CDKN2A TP53
8	spitz nevus	10.3	CDKN2A TP53
9	bladder carcinoma in situ	10.3	CDKN2A TP53
10	vulva squamous cell carcinoma	10.3	CDKN2A TP53
11	scrotal carcinoma	10.3	CDKN2A TP53
12	thyroid lymphoma	10.3	CDKN2A TP53
13	vulvar disease	10.3	CDKN2A TP53
14	nasal cavity adenocarcinoma	10.3	CDKN2A TP53
15	bartholin's gland disease	10.3	CDKN2A TP53
16	megaesophagus	10.3	CDKN2A TP53
17	glycogen-rich clear cell breast carcinoma	10.3	CDKN2A TP53
18	gastric adenosquamous carcinoma	10.3	CDKN2A TP53
19	anogenital venereal wart	10.3	CDKN2A TP53
20	cervix uteri carcinoma in situ	10.3	CDKN2A TP53
21	uterus carcinoma in situ	10.3	CDKN2A TP53
22	oral leukoplakia	10.3	CDKN2A TP53
23	meningeal melanomatosis	10.3	CDKN2A TP53
24	hyperplastic polyposis syndrome	10.3	APC TP53
25	dedifferentiated liposarcoma	10.3	CDKN2A TP53
26	endocervical adenocarcinoma	10.3	CDKN2A TP53
27	mutyh-associated polyposis	10.3	APC TP53
28	penile disease	10.3	CDKN2A TP53
29	cervix small cell carcinoma	10.3	CDKN2A TP53
30	necrotizing sialometaplasia	10.3	CDKN2A TP53
31	verrucous carcinoma	10.3	CDKN2A TP53
32	basaloid squamous cell carcinoma	10.3	CDKN2A TP53
33	tongue disease	10.3	CDKN2A TP53
34	optic nerve neoplasm	10.3	CDKN2A TP53
35	juvenile pilocytic astrocytoma	10.2	CDKN2A TP53
36	tonsil cancer	10.2	CDKN2A TP53
37	pre-malignant neoplasm	10.2	CDKN2A TP53
38	polyposis syndrome, hereditary mixed, 1	10.2	APC MLH1
39	vulva cancer	10.2	CDKN2A TP53
40	anaplastic oligodendroglioma	10.2	CDKN2A MGMT
41	squamous cell papilloma	10.2	CDKN2A TP53
42	adult hepatocellular carcinoma	10.2	PIK3CA TP53
43	malignant spiradenoma	10.2	PIK3CA TP53
44	papilloma	10.2
45	breast squamous cell carcinoma	10.2	PIK3CA TP53
46	laryngeal disease	10.2	CDKN2A TP53
47	breast giant fibroadenoma	10.2	CDKN2A MGMT
48	richter's syndrome	10.2	MLH1 TP53
49	barrett's adenocarcinoma	10.2	CDKN2A TP53
50	oropharynx cancer	10.2	CDKN2A TP53

Graphical network of the top 20 diseases related to Anal Squamous Cell Carcinoma:

Sources

Symptoms & Phenotypes for Anal Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

²⁷ (show all 25)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-116	9.8	PIK3CA
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-121	9.8	FBXW7
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-122	9.8	FBXW7
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-133	9.8	APC
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-152	9.8	FBXW7
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-157	9.8	FBXW7 PIK3CA
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-16	9.8	AKT1 PIK3CA
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-166	9.8	PIK3CA
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-177	9.8	AKT1 APC FBXW7 PIK3CA
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-183	9.8	FBXW7
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-190	9.8	PIK3CA
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-192	9.8	APC
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-202	9.8	APC
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-29	9.8	APC
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-42	9.8	AKT1 PIK3CA
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	9.8	FBXW7
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-49	9.8	APC PIK3CA
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-50	9.8	AKT1
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-52	9.8	FBXW7
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-70	9.8	AKT1
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-74	9.8	APC
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-79	9.8	AKT1
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	9.8	AKT1
24	Decreased CDKN1A mRNA expression	GR00389-S-1	9.13	FBXW7 TP53
25	Decreased CDKN1A mRNA expression	GR00389-S-2	9.13	TP53

MGI Mouse Phenotypes related to Anal Squamous Cell Carcinoma:

⁴⁷ (show all 16)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	endocrine/exocrine gland	MP:0005379	10.11	AKT1 APC CDKN2A FBXW7 MGMT MLH1
2	homeostasis/metabolism	MP:0005376	10.1	AKT1 APC CDKN2A FBXW7 MGMT MLH1
3	cellular	MP:0005384	10.09	AKT1 APC CDKN2A FBXW7 MLH1 PIK3CA
4	cardiovascular system	MP:0005385	10.03	AKT1 APC CDKN2A FBXW7 PIK3CA TP53
5	immune system	MP:0005387	10.02	AKT1 APC CDKN2A FBXW7 MLH1 PIK3CA
6	mortality/aging	MP:0010768	10.01	AKT1 APC CDKN2A FBXW7 MGMT MLH1
7	embryo	MP:0005380	10	AKT1 APC CDKN2A FBXW7 PIK3CA TP53
8	integument	MP:0010771	10	AKT1 APC CDKN2A FBXW7 MLH1 PIK3CA
9	digestive/alimentary	MP:0005381	9.93	APC CDKN2A FBXW7 MLH1 TP53
10	neoplasm	MP:0002006	9.92	AKT1 APC CDKN2A FBXW7 MGMT MLH1
11	liver/biliary system	MP:0005370	9.83	AKT1 APC CDKN2A FBXW7 TP53
12	muscle	MP:0005369	9.77	AKT1 APC CDKN2A PIK3CA TP53
13	reproductive system	MP:0005389	9.63	AKT1 APC CDKN2A MLH1 PIK3CA TP53
14	no phenotypic analysis	MP:0003012	9.56	CDKN2A MGMT PIK3CA TP53
15	respiratory system	MP:0005388	9.43	AKT1 CDKN2A FBXW7 MGMT MLH1 TP53
16	vision/eye	MP:0005391	9.1	APC CDKN2A FBXW7 MLH1 PIK3CA TP53

Sources

Drugs & Therapeutics for Anal Squamous Cell Carcinoma

Drugs for Anal Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Immunologic Factors

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Fluorouracil

Approved

Phase 3,Phase 2,Phase 1,Early Phase 1

51-21-8

3385

Cisplatin

Approved

Phase 3,Phase 2

15663-27-1

441203 84093 2767

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 2

33069-62-4

36314

Capecitabine

Approved, Investigational

Phase 3,Phase 2

154361-50-9

60953

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1,Early Phase 1

Antimetabolites

Phase 3,Phase 2,Phase 1,Early Phase 1

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1,Early Phase 1

Antimitotic Agents

Phase 3,Phase 2

Albumin-Bound Paclitaxel

Phase 3,Phase 2

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2

Alkylating Agents

Phase 3,Phase 2,Phase 1,Early Phase 1

Nucleic Acid Synthesis Inhibitors

Phase 3,Phase 2,Phase 1,Early Phase 1

Mitomycins

Phase 3,Phase 2,Phase 1,Early Phase 1

Antibiotics, Antitubercular

Phase 3,Phase 2,Phase 1,Early Phase 1

Anti-Bacterial Agents

Phase 3,Phase 2,Phase 1,Early Phase 1

Carboplatin

Approved

Phase 2

41575-94-4

38904 10339178 498142

Cetuximab

Approved

Phase 2

205923-56-4

56842117 2333

Panitumumab

Approved, Investigational

Phase 2,Phase 1

339177-26-3

50070211

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

6857599 5310940 9887054 43805

Atezolizumab

Approved, Investigational

Phase 2

1380723-44-3

Docetaxel

Approved, Investigational

Phase 2

114977-28-5

148124

Valproic Acid

Approved, Investigational

Phase 2

99-66-1

3121

Pembrolizumab

Approved

Phase 2

1374853-91-4

Antineoplastic Agents, Immunological

Phase 2,Phase 1

Protein Kinase Inhibitors

Phase 2

ON 01910

Phase 2

Immunoglobulins

Phase 2,Phase 1

Antibodies

Phase 2,Phase 1

Antibodies, Monoclonal

Phase 2,Phase 1

Antimanic Agents

Phase 2

Tranquilizing Agents

Phase 2

Central Nervous System Depressants

Phase 2

Anticonvulsants

Phase 2

Neurotransmitter Agents

Phase 2

GABA Agents

Phase 2

Psychotropic Drugs

Phase 2

taxane

Phase 2

Fludarabine

Approved

Phase 1

75607-67-9, 21679-14-1

30751

nivolumab

Approved

Phase 1

946414-94-4

Cyclophosphamide

Approved, Investigational

Phase 1

6055-19-2, 50-18-0

2907

Ipilimumab

Approved

Phase 1

477202-00-9

Manganese

Approved, Nutraceutical

Phase 1

7439-96-5

27854

Vaccines

Phase 1

Antineoplastic Agents, Alkylating

Phase 1

Antirheumatic Agents

Phase 1

Dimenhydrinate

Approved

523-87-5

441281

Hydrogen peroxide

Approved, Vet_approved

7722-84-1

784

Ethanol

Approved

64-17-5

702

Pharmaceutical Solutions

Interventional clinical trials:

(show all 45)

#	Name	Status	NCT ID	Phase	Drugs
1	Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV	Withdrawn	NCT01663558	Phase 4	imiquimod
2	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer	Unknown status	NCT00003652	Phase 3	cisplatin;fluorouracil
3	Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer	Completed	NCT00003596	Phase 3	cisplatin;fluorouracil;mitomycin C
4	Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer	Completed	NCT00025090	Phase 3	cisplatin;fluorouracil;mitomycin C
5	Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy	Recruiting	NCT02369939	Phase 3	Mitomycin C;5-Fluorouracil
6	Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients	Enrolling by invitation	NCT02526953	Phase 3	Paclitaxel;Capecitabine;Capecitabine;Mitomycins;Mitomycins
7	Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer	Terminated	NCT00068744	Phase 2, Phase 3	cisplatin;fluorouracil;mitomycin C
8	International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel	Unknown status	NCT02051868	Phase 2	Cisplatin;5-Fluorouracil (5-FU);Carboplatin;Paclitaxel
9	Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer	Unknown status	NCT00955240	Phase 2	cisplatin;fluorouracil
10	Vectibix for the Treatment of Anal Cancer	Completed	NCT01285778	Phase 2	panitumumab, mytomicin C, 5-FU, radiation
11	Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer	Completed	NCT00324415	Phase 2	cisplatin;fluorouracil
12	Oral Rigosertib for Squamous Cell Carcinoma	Completed	NCT01807546	Phase 2	rigosertib
13	Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer	Completed	NCT00423293	Phase 2	fluorouracil;mitomycin C
14	Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer	Completed	NCT00093379	Phase 2	Capecitabine;Oxaliplatin
15	A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma	Recruiting	NCT03519295	Phase 2	MPDL3280A;mDCF
16	Prebiotics and Probiotics During Definitive Treatment With Chemotherapy-radiotherapy SCC of the Anal Canal (BISQUIT)	Recruiting	NCT03870607	Phase 2
17	Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection	Recruiting	NCT02437851	Phase 2
18	Avelumab With Valproic Acid in Virus-associated Cancer	Recruiting	NCT03357757	Phase 2	Valproic Acid
19	Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)	Recruiting	NCT02628067	Phase 2
20	Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus	Active, not recruiting	NCT01581840	Phase 1, Phase 2	radiochemotherapy;Panitumumab
21	Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma	Active, not recruiting	NCT02402842	Phase 2	Docetaxel, Cisplatin and 5-Fluorouracil
22	Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer	Active, not recruiting	NCT00316888	Phase 2	cisplatin;fluorouracil
23	Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer	Active, not recruiting	NCT02560298	Phase 2	Capecitabine;Carboplatin;Cisplatin;Fluorouracil;Paclitaxel
24	A Phase 1/2 Trial of SRA737 in Subjects With Advanced Cancer	Active, not recruiting	NCT02797964	Phase 1, Phase 2	SRA737
25	A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus	Withdrawn	NCT02857608	Phase 2	Lymphoseek
26	A Phase 1 Study in Participants With Advanced Cancer	Completed	NCT01115790	Phase 1	Prexasertib
27	Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.	Completed	NCT00423254	Phase 1
28	Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer	Recruiting	NCT03386500	Phase 1	BMX-001
29	HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA	Recruiting	NCT02379520	Phase 1	Cytoxan;Fludarabine
30	Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery	Recruiting	NCT02408861	Phase 1
31	SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas	Recruiting	NCT03894618	Phase 1	SL-279252
32	ART: Anal Squamous Cell Carcinoma: Investigation of Functional Imaging During chemoRadioTherapy	Completed	NCT02145416
33	Molecular Biology of Anal Cancer in HIV-Positive Patients	Completed	NCT00952874
34	Evaluation by MRI of Anal Canal Cell Carcinoma: is There Predictive Factor?	Completed	NCT03469596
35	Anal Dysplasia in Patients With Inflammatory Bowel Disease	Completed	NCT01653054	Not Applicable
36	OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer	Completed	NCT00900302
37	Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of Patients	Recruiting	NCT01877135
38	Study of Anal Cytologies in Patients With High Grade Cervical Intraepithelial Neoplasia (CIN II and III)	Recruiting	NCT03241680	Not Applicable
39	Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men	Recruiting	NCT02816879	Not Applicable
40	Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer	Recruiting	NCT02140021	Not Applicable
41	Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma	Active, not recruiting	NCT01858025	Early Phase 1	5-fluorouracil;Mitomycin-C
42	Seville Cohort of People Living With HIV at Risk for Anal Cancer	Enrolling by invitation	NCT03713229
43	Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.	Not yet recruiting	NCT03061435	Not Applicable
44	Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays	Terminated	NCT02407561
45	Study to Determine the Feasibility of Sentinel Node Biopsy in Patients With Anal Cancer	Withdrawn	NCT02162641

Search NIH Clinical Center for Anal Squamous Cell Carcinoma

Sources

Genetic Tests for Anal Squamous Cell Carcinoma

Sources

Anatomical Context for Anal Squamous Cell Carcinoma

MalaCards organs/tissues related to Anal Squamous Cell Carcinoma:

⁴²

Lymph Node, Testes, T Cells, Colon, Cervix

Sources

Publications for Anal Squamous Cell Carcinoma

Articles related to Anal Squamous Cell Carcinoma:

(show top 50) (show all 117)

#	Title	Authors	Year
1	Increased risk of anal squamous cell carcinoma in HIV-positive men with prior hepatitis B virus infection. ( 30325778 )	Aldersley J...Gabuzda D	2019
2	Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review. ( 30636052 )	Sclafani F...Goldstein D	2019
3	The Role of Multiagent Chemoradiation in the Management and Prognosis of Anal Squamous Cell Carcinoma. ( 30644029 )	Goffredo P...Hassan I	2019
4	Intensity-modulated radiation therapy of anal squamous cell carcinoma: Relationship between delineation quality and regional recurrence. ( 30773194 )	Rouard N...Serre AA	2019
5	Treatment outcomes of patients with localized anal squamous cell carcinoma according to HIV infection: systematic review and meta-analysis. ( 30788159 )	Camandaroba MPG...Riechelmann RP	2019
6	Distinguishing Anal Squamous Cell Carcinoma and Rectal Squamous Cell Carcinoma in Secondary Data Sets. ( 29420432 )	Leeds I.L....Fang S.H.	2018
7	Salvage Surgery for Locoregional Failure in Anal Squamous Cell Carcinoma. ( 29337772 )	Guerra G.R....Heriot A.G.	2018
8	Radiotherapy for anal squamous cell carcinoma: must the upper pelvic nodes and the inguinal nodes be treated? ( 29514401 )	Thompson S.R....Goldstein D.	2018
9	Complex Reconstruction with Flaps After Abdominoperineal Resection and Groin Dissection for Anal Squamous Cell Carcinoma: A Difficult Case Involving Many Specialities. ( 29339717 )	Reali C....Hompes R.	2018
10	Programmed death-ligand 1 expression correlates with diminished CD8+ T cell infiltration and predicts poor prognosis in anal squamous cell carcinoma patients. ( 29296096 )	Zhao Y.J....Pan Z.Z.	2018
11	Association of HIV Status With Outcomes of Anal Squamous Cell Carcinoma in the Era of Highly Active Antiretroviral Therapy. ( 28975226 )	Bryant A.K....Murphy J.D.	2018
12	HPV positive, wild type TP53, and p16 overexpression correlate with the absence of residual tumors after chemoradiotherapy in anal squamous cell carcinoma. ( 29466950 )	Soares P.C....Burbano R.M.R.	2018
13	Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma. ( 29416628 )	Cacheux W....LiA"vre A.	2018
14	Anal squamous cell carcinoma - State of the art management and future perspectives. ( 29494827 )	Martin D....Fokas E.	2018
15	The prognostic value of HPV combined p16 status in patients with anal squamous cell carcinoma: a meta-analysis. ( 29487716 )	Sun G....Zhao E.	2018
16	Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. ( 30042063 )	Kim S...Borg C	2018
17	Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma. ( 30054279 )	Cabel L...Cacheux W	2018
18	Oestrogen receptor can be expressed by normal and dysplastic anal squamous epithelia but only rarely by anal squamous cell carcinoma. ( 30062743 )	Wong NACS	2018
19	Anal squamous cell carcinoma: are we improving outcomes? ( 30159994 )	Mackowski A...Platell C	2018
20	Image-guided Interstitial Brachytherapy in the Management of Metastasized Anal Squamous Cell Carcinoma. ( 30194195 )	Heinze C...Powerski MJ	2018
21	ASO Author Reflections: The Role of Tumor Size in the Prognosis of Anal Squamous Cell Carcinoma: A Validation on the New American Joint Committee on Cancer Subclassification of Stage IIA and B. ( 30367300 )	Goffredo P...Hassan I	2018
22	Rising Incidence and Improved Survival of Anal Squamous Cell Carcinoma in Norway, 1987-2016. ( 30415990 )	Guren MG...M?ller B	2018
23	Radiation Therapy for Anal Squamous Cell Carcinoma: A Retrospective Multicenter Study. ( 30504412 )	Koh HK...Kim MS	2018
24	Multiple primary malignancies in patients with anal squamous cell carcinoma. ( 30505585 )	Li D...Jabbour SK	2018
25	Demographic disparities in delay of definitive chemoradiation for anal squamous cell carcinoma: a nationwide analysis. ( 30603130 )	Ramey SJ...Yechieli R	2018
26	Prognostic Significance of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Anal Squamous Cell Carcinoma: A Systematic Review and a Meta-Analysis. ( 30627062 )	Sadeghi R...Treglia G	2018
27	Chemotherapeutic Response and Survival for Patients With an Anal Squamous Cell Carcinoma and Low Hemoglobin Levels. ( 30630304 )	Naqvi A...Smolarek S	2018
28	Anal Squamous Cell Carcinoma in a Patient with Myasthenia Gravis: Is Immunosuppression the Main Underlying Etiology? ( 29348988 )	Masab M....Saif M.W.	2017
29	Survival rate variation with different histological subtypes of poor prognostic male anal squamous cell carcinoma: a population-based study. ( 29137429 )	Wan Z....Li J.	2017
30	The promise of immunotherapy in anal squamous cell carcinoma: a novel approach for an orphan disease. ( 29315288 )	Johnson B....Eng C.	2017
31	Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy. ( 28334399 )	Yanik E.L....Taube J.M.	2017
32	Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study). ( 28841909 )	Kim S....Borg C.	2017
33	High-risk human papillomavirus in anal squamous cell carcinoma: a 'conservative' leading role. ( 28453691 )	Ravenda P.S....Fazio N.	2017
34	Prognostic relevance of human papillomavirus infection in anal squamous cell carcinoma: analysis of the national cancer data base. ( 29299360 )	Jhaveri J....Landry J.C.	2017
35	Recurrent anal squamous cell carcinoma in a patient who refuses end colostomy: What to do? ( 29100741 )	Tremblay J.F....Pocard M.	2017
36	Coincidence or not? A rare case of rectal leiomyosarcoma amidst incidental findings of anal squamous cell carcinoma: case presentation and literature review. ( 28959428 )	Iwasiuk G....Nealy J.	2017
37	Dosimetric advantages and clinical outcomes of simultaneous integrated boost intensity-modulated radiotherapy for anal squamous cell carcinoma. ( 28893059 )	Sakanaka K....Hiraoka M.	2017
38	The Impact of Intensity Modulated Radiation Therapy on Hospitalization Outcomes in the SEER-Medicare Population With Anal Squamous Cell Carcinoma. ( 28258896 )	Pollom E.L....Chang D.T.	2017
39	Impact of Intensity-Modulated Radiotherapy on Health Care Costs of Patients With Anal Squamous Cell Carcinoma. ( 29035618 )	Chin A.L....Chang D.T.	2017
40	Targeting phosphorylation of STAT3 delays tumor growth in HPV-negative anal squamous cell carcinoma mouse model. ( 28747781 )	Bu L.L....Sun Z.J.	2017
41	Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy. ( 29122359 )	RAPdel F....Yuan J.	2017
42	Predictors of acute toxicities during definitive chemoradiation using intensity-modulated radiotherapy for anal squamous cell carcinoma. ( 25984929 )	Julie D.A....Goodman K.A.	2016
43	A Prolapsing Pile Revealing Anal Squamous Cell Carcinoma. ( 27125703 )	Daniel F....Ziade N.	2016
44	A combined modality therapeutic approach to metastatic anal squamous cell carcinoma with systemic chemotherapy and local therapy to sites of disease: case report and review of literature. ( 27284490 )	Gnanajothy R....Peterson L.L.	2016
45	Anal Squamous Cell Carcinoma: An Infrequent Challenge in the Management of Ulcerative Colitis Under Combination Therapy. ( 26818664 )	Kotze P.G....Zacharias P.	2016
46	A Patient with HIV-Associated Metastatic Anal Squamous Cell Carcinoma Receiving Multimodality Therapy with Curative Intent: Case Report and Review of the Literature. ( 26961789 )	Kim S.S....Ko A.H.	2016
47	Chemoradiotherapy for anal squamous cell carcinoma. ( 27118047 )	Houlihan O.A....O'Neill B.D.	2016
48	Anal squamous cell carcinoma in Crohn's disease. ( 27773118 )	Lea V....Li J.J.	2016
49	Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. ( 27052656 )	Chung J.H....Ali S.M.	2016
50	Metastatic rectal adenocarcinoma and anal squamous cell carcinoma masquerading as vulvar lymphangioma circumscriptum. ( 27616148 )	Soh J.M....Mercurio M.G.	2016

Sources

Genes for Anal Squamous Cell Carcinoma

Genes related to Anal Squamous Cell Carcinoma (0 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	22.82	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	21.31	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	TP53	Tumor Protein P53	Protein Coding	21.28	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	20.23	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	APC	APC Regulator Of WNT Signaling Pathway	Protein Coding	17.32	GeneCards inferred via : Publications (show sections)
6	MLH1	MutL Homolog 1	Protein Coding	17.32	GeneCards inferred via : Publications (show sections)
7	FBXW7	F-Box And WD Repeat Domain Containing 7	Protein Coding	16.97	GeneCards inferred via : Publications (show sections)
8	MGMT	O-6-Methylguanine-DNA Methyltransferase	Protein Coding	16.97	GeneCards inferred via : Publications (show sections)

Sources

Variations for Anal Squamous Cell Carcinoma

Sources

Expression for Anal Squamous Cell Carcinoma

Search GEO for disease gene expression data for Anal Squamous Cell Carcinoma.

Sources

Pathways for Anal Squamous Cell Carcinoma

Pathways related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 71)

#	Super pathways	Score	Top Affiliating Genes
1	PI3K-Akt signaling pathway ³⁸ Show member pathways Human papillomavirus infection ³⁸	12.83	AKT1 APC PIK3CA TP53
2	Human cytomegalovirus infection ³⁸ Show member pathways Human immunodeficiency virus 1 infection ³⁸ Kaposi sarcoma-associated herpesvirus infection ³⁸	12.82	AKT1 CDKN2A PIK3CA TP53
3	Regulation of TP53 Activity ⁶⁷ Show member pathways Regulation of TP53 Activity through Association with Co-factors ⁶⁷ Regulation of TP53 Activity through Methylation ⁶⁷ Regulation of TP53 Activity through Phosphorylation ⁶⁷ Transcriptional Regulation by TP53 ⁶⁷	12.81	AKT1 CDKN2A MLH1 TP53
4	Apoptosis Modulation and Signaling ¹ Show member pathways Apoptosis ³⁸ Apoptosis ¹ Apoptosis and survival Apoptotic TNF-family pathways ²³ Apoptosis Signaling Pathways ⁶⁶ Death Receptor Signaling ⁶⁸	12.64	AKT1 CDKN2A PIK3CA TP53
5	Endometrial cancer ³⁸ Show member pathways Acute myeloid leukemia ³⁸ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁷ Chronic myeloid leukemia ³⁸ Colorectal cancer ³⁸ Pancreatic cancer ³⁸ Prostate cancer ³⁸ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁸	12.63	AKT1 APC CDKN2A MLH1 PIK3CA TP53
6	Pathways in cancer ³⁸	12.57	AKT1 APC CDKN2A MLH1 PIK3CA TP53
7	Development HGF signaling pathway ²³ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²³ Apoptosis and survival NGF signaling pathway ²³ Apoptosis and survival Role of CDK5 in neuronal death and survival ²³ Development Neurotrophin family signaling ²³ MET activates PTPN11 ⁶⁷ MET activates STAT3 ⁶⁷ Neurotrophin signaling pathway ³⁸ Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) ¹ Signaling of Hepatocyte Growth Factor Receptor ¹	12.52	AKT1 APC PIK3CA TP53
8	Glioma ³⁸ Show member pathways Endocrine resistance ³⁸ Melanoma ³⁸ Non-small cell lung cancer ³⁸ Signaling Pathways in Glioblastoma ¹	12.51	AKT1 CDKN2A PIK3CA TP53
9	ErbB signaling pathway ¹ ³⁸ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶² EGFR tyrosine kinase inhibitor resistance ³⁸ Renal cell carcinoma ³⁸ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.47	AKT1 PIK3CA TP53
10	Gastric cancer ³⁸ Show member pathways Breast cancer ³⁸ Hepatocellular carcinoma ³⁸	12.4	AKT1 APC CDKN2A MLH1 PIK3CA TP53
11	Apoptosis Pathway ⁷³ Show member pathways Akt Pathway ⁷³ NF-kappaB Pathway ⁷³	12.33	AKT1 PIK3CA TP53
12	MicroRNAs in cancer ³⁸	12.33	APC CDKN2A PIK3CA TP53
13	AMP-activated Protein Kinase (AMPK) Signaling ¹ Show member pathways AMPK signaling pathway ³⁸ AMPK Signaling Pathway ⁶⁸	12.32	AKT1 PIK3CA TP53
14	DNA Damage ⁴	12.32	CDKN2A MGMT MLH1 TP53
15	WNT Signaling ⁶⁵	12.31	AKT1 APC TP53
16	mTOR signaling pathway (KEGG) ⁶⁶ Show member pathways mTOR signaling pathway ³⁸	12.3	AKT1 APC PIK3CA TP53
17	Development IGF-1 receptor signaling ²³ Show member pathways IL-4 Signaling Pathway ¹ Immune response IL-4 signaling pathway ²³ Signal transduction AKT signaling ²³	12.28	AKT1 PIK3CA TP53
18	Cell cycle ³⁸ ¹	12.24	APC CDKN2A TP53
19	Toll Comparative Pathway ⁶⁵ Show member pathways IL-1 Pathway ⁶⁵ Immune response MIF in innate immunity response ²³ iNOS Signaling ⁶⁵ TLR-TRIF Pathway ⁶⁵	12.2	AKT1 PIK3CA TP53
20	Human T-cell leukemia virus 1 infection ³⁸	12.2	AKT1 APC CDKN2A PIK3CA TP53
21	Proteoglycans in cancer ³⁸	12.16	AKT1 PIK3CA TP53
22	Viral carcinogenesis ³⁸	12.16	CDKN2A PIK3CA TP53
23	MAPK Signaling: Mitogen Stimulation Pathway ⁶⁶ Show member pathways Akt Signaling Pathway ⁶⁶	12.09	AKT1 PIK3CA TP53
24	mTOR Pathway ⁷³ Show member pathways Insulin Pathway ⁷³ TGF-beta Pathway ⁷³	12.03	AKT1 PIK3CA TP53
25	Colorectal Cancer Metastasis ⁶⁵	12.01	AKT1 APC MLH1 TP53
26	AKT Signaling Pathway ⁶⁸	11.99	AKT1 PIK3CA TP53
27	Longevity regulating pathway ³⁸ Show member pathways Longevity regulating pathway - multiple species ³⁸	11.99	AKT1 PIK3CA TP53
28	Cellular senescence (KEGG) ³⁸	11.98	AKT1 CDKN2A PIK3CA TP53
29	Fluid shear stress and atherosclerosis ³⁸	11.95	AKT1 PIK3CA TP53
30	Signaling pathways regulating pluripotency of stem cells ³⁸	11.94	AKT1 APC PIK3CA
31	Direct p53 effectors ¹	11.91	APC MLH1 TP53
32	MAPK Pathway ⁷³ Show member pathways Toll-like Receptor Pathway ⁷³	11.87	AKT1 PIK3CA TP53
33	Sphingolipid signaling pathway ³⁸	11.85	AKT1 PIK3CA TP53
34	Thyroid hormone signaling pathway ³⁸	11.83	AKT1 PIK3CA TP53
35	Small cell lung cancer ³⁸	11.72	AKT1 PIK3CA TP53
36	Regulation of TP53 Expression and Degradation ⁶⁷ Show member pathways Regulation of TP53 Degradation ⁶⁷ Regulation of TP53 Expression ⁶⁷	11.61	AKT1 CDKN2A TP53
37	DNA Damage Response (only ATM dependent) ¹	11.61	AKT1 APC CDKN2A PIK3CA TP53
38	Pathways Affected in Adenoid Cystic Carcinoma ¹	11.55	AKT1 FBXW7 PIK3CA TP53
39	p75(NTR)-mediated signaling ¹ Show member pathways Ceramide signalling ⁶⁷ NFG and proNGF binds to p75NTR ⁶⁷	11.52	AKT1 PIK3CA TP53
40	Central carbon metabolism in cancer ³⁸	11.5	AKT1 PIK3CA TP53
41	DNA damage_Role of Brca1 and Brca2 in DNA repair ²³	11.44	AKT1 MLH1 TP53
42	Glioblastoma Multiforme ⁶⁵	11.4	AKT1 APC CDKN2A MGMT TP53
43	Busulfan Pathway, Pharmacodynamics ⁶² Show member pathways Catalytic cycle of mammalian Flavin-containing MonoOxygenases (FMOs) ¹ FMO oxidises nucleophiles ⁶⁷	11.39	MGMT MLH1
44	Carbohydrate digestion and absorption ³⁸	11.39	AKT1 PIK3CA
45	Deactivation of the beta-catenin transactivating complex ⁶⁷	11.38	AKT1 APC
46	Insulin Pathway ¹	11.37	AKT1 PIK3CA
47	Copper homeostasis ¹	11.36	AKT1 APC PIK3CA TP53
48	Doxorubicin Pathway, Pharmacokinetics ⁶² Show member pathways Doxorubicin Pathway (Cancer Cell), Pharmacodynamics ⁶²	11.34	MLH1 TP53
49	Ovarian tumor domain proteases ⁶⁷	11.3	APC TP53
50	CXCR3-mediated signaling events ¹	11.25	AKT1 PIK3CA

Sources

GO Terms for Anal Squamous Cell Carcinoma

Cellular components related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	nucleoplasm	GO:0005654	9.17	AKT1 APC CDKN2A FBXW7 MGMT MLH1

Biological processes related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 16)

#	Name	GO ID	Score	Top Affiliating Genes
1	cytokine-mediated signaling pathway	GO:0019221	9.72	AKT1 PIK3CA TP53
2	cell cycle arrest	GO:0007050	9.58	APC CDKN2A TP53
3	protein destabilization	GO:0031648	9.56	CDKN2A FBXW7
4	negative regulation of Notch signaling pathway	GO:0045746	9.54	AKT1 FBXW7
5	protein kinase B signaling	GO:0043491	9.52	AKT1 PIK3CA
6	cellular response to ionizing radiation	GO:0071479	9.51	MGMT TP53
7	phosphatidylinositol 3-kinase signaling	GO:0014065	9.49	AKT1 PIK3CA
8	negative regulation of cyclin-dependent protein serine/threonine kinase activity	GO:0045736	9.48	APC CDKN2A
9	vasculature development	GO:0001944	9.46	FBXW7 PIK3CA
10	apoptotic mitochondrial changes	GO:0008637	9.43	AKT1 CDKN2A
11	negative regulation of macroautophagy	GO:0016242	9.37	AKT1 PIK3CA
12	mammary gland epithelial cell differentiation	GO:0060644	9.32	AKT1 MGMT
13	replicative senescence	GO:0090399	9.26	CDKN2A TP53
14	positive regulation of apoptotic process	GO:0043065	9.26	AKT1 APC CDKN2A TP53
15	anoikis	GO:0043276	9.16	AKT1 PIK3CA
16	cellular response to DNA damage stimulus	GO:0006974	9.02	AKT1 APC MGMT MLH1 TP53

Molecular functions related to Anal Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	ubiquitin protein ligase binding	GO:0031625	9.43	APC FBXW7 TP53
2	disordered domain specific binding	GO:0097718	9.16	CDKN2A TP53
3	protein phosphatase 2A binding	GO:0051721	8.96	AKT1 TP53
4	protein kinase binding	GO:0019901	8.92	AKT1 APC CDKN2A TP53

Sources

Sources for Anal Squamous Cell Carcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia